stockrowDBV Technologies S.A.
DBVTDBV Technologies S.A.’s revenue for fiscal 2025 (year ended December 2025) was $5.6 million, up 35.8% from fiscal 2024.
- Revenue
- −42.9%
- EPS
- +40.4%
- Free cash flow
- −64.9%
Quarter to September 2026, against a year earlier
Follow DBVT
Alert me
DBV Technologies S.A. (DBVT) Return on invested capital
DBV Technologies S.A.'s return on invested capital over the twelve months to 30 September 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −14,425.0% (fiscal 2019) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 280.50 |
| FY2021 | −280.5% | 744.88 |
| FY2020 | −1,025.4% | 13,399.64 |
| FY2019 | −14,425.0% | (14,425.02) |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | 840.20 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| IMMX Immix Biopharma, Inc. compare | 0.00% |
| WVE WAVE Life Sciences Ltd. compare | 0.00% |
| KURA Kura Oncology, Inc. compare | 0.00% |
| AVBP ArriVent BioPharma, Inc. compare | 0.00% |
| ACHV Achieve Life Sciences, Inc. compare | 0.00% |
| DBVT DBV Technologies S.A. | 0.00% |
| DSGN Design Therapeutics, Inc. compare | 0.00% |
| HELP Cybin Inc. compare | −137.9% |
| FDMT 4D Molecular Therapeutics, Inc. compare | −186.9% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)